Harvest of Human Mesenchymal Stem Cells from Microcarriers

September 15, 2017
Aletta C. Schnitzler, Julie Murrell, Susan Rigby, Manjula Aysola
Volume 2017 eBook, Issue 2
Page Number: 23–26

Traditional planar culture formats are being superceded by microcarriers for large-scale cell therapy manufacturing.

Hundreds of clinical trials are currently underway testing the merits of cell therapies, as evidenced by the clinicaltrials.gov database and highlighted by the Alliance for Regenerative Medicine. A number of trials and commercially marketed products use adult, multipotent cells such as human mesenchymal stem/stromal cells (hMSCs). Large-scale industrialized production of these cells is necessary to continue their advancement through human clinical trials and commercialization as therapeutics. However, achieving this level of production while meeting rigorous quality standards will depend on further progress in the areas of cell culture and scale-up, characterization, enrichment, and purification to deliver a consistent and reproducible supply of cells. 

Download the

.

 

Article Details

BioPharm International
eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 23–26

Citation

When referring to this article, please cite it as A. Schnitzler et al., "Harvest of Human Mesenchymal Stem Cells from Microcarriers," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).